Continuous temperature tracking helps manage infection risk after CAR T-cell therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CAR T-cell therapies have been used to treat cancer patients since 2011, but infection-related adverse events remain a significant hurdle. Often, fever is one of the earliest warning signs of clinical deterioration and a potentially life-threatening condition.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ruth Phillips, RN, MS
Vice president of medical affairs, Blue Spark Technologies
Table of Contents

YOU MAY BE INTERESTED IN

FDA granted full approval of Tecelra (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. 
Ruth Phillips, RN, MS
Vice president of medical affairs, Blue Spark Technologies

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login